Compare FMC Corp (FMC) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs Incyte Corporation — how do they compare? FMC Corp trades at $10.5 (market cap $1.30B), while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 18.9× FMC Corp's market cap, and FMC Corp pays a 3.07% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| FMC | INCY | |
|---|---|---|
Market Cap | $1.30B | $24.54B |
Sector | Basic Materials | Health |
52-Week High | $40.69 | $129.93 |
52-Week Low | $10.01 | $81.61 |
Enterprise Value | $5.11B | $20.04B |
Dividend Yield | 3.07% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
